Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review
ConclusionFurther research is needed to explain the interindividual variability of the ruxolitinib pharmacokinetic variables and to optimize individual treatment. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - March 31, 2023 Category: Drugs & Pharmacology Source Type: research
Neither Gastric Bypass Surgery Nor Diet-Induced Weight-Loss Affect OATP1B1 Activity as Measured by Rosuvastatin Oral Clearance
ConclusionsNeither body weight, weight loss nor RYGB per se seem to affect OATP1B1 activity to a clinically relevant degree. Overall, the observed changes in rosuvastatin pharmacokinetics were minor, and unlikely to be of clinical relevance. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - March 29, 2023 Category: Drugs & Pharmacology Source Type: research
General Framework to Quantitatively Predict Pharmacokinetic Induction Drug –Drug Interactions Using In Vitro Data
ConclusionThis research presents a rapid screening tool to identify the magnitude of potential DDIs utilising in vitro data which can be highly advantageous in early drug development. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - March 29, 2023 Category: Drugs & Pharmacology Source Type: research
Neither Gastric Bypass Surgery Nor Diet-Induced Weight-Loss Affect OATP1B1 Activity as Measured by Rosuvastatin Oral Clearance
ConclusionsNeither body weight, weight loss nor RYGB per se seem to affect OATP1B1 activity to a clinically relevant degree. Overall, the observed changes in rosuvastatin pharmacokinetics were minor, and unlikely to be of clinical relevance. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - March 29, 2023 Category: Drugs & Pharmacology Source Type: research
General Framework to Quantitatively Predict Pharmacokinetic Induction Drug –Drug Interactions Using In Vitro Data
ConclusionThis research presents a rapid screening tool to identify the magnitude of potential DDIs utilising in vitro data which can be highly advantageous in early drug development. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - March 29, 2023 Category: Drugs & Pharmacology Source Type: research
Optimization of β-Lactam Dosing Regimens in Neonatal Infections: Continuous and Extended Administration versus Intermittent Administration
ConclusionsContinuous infusion after a loading dose leads to a higher PTA compared with continuous, intermittent or prolonged infusion, and therefore has the potential to improve treatment with β-lactam antibiotics in neonates. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - March 27, 2023 Category: Drugs & Pharmacology Source Type: research
The Pharmacokinetics and Target Attainment of Antimicrobial Drugs Throughout Pregnancy: Part III Non-penicillin and Non-cephalosporin Drugs
ConclusionThis systematic literature review shows that a very limited number of studies have been performed on the PK of antimicrobials drugs —other than cephalosporins and penicillins—in pregnant women. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - March 20, 2023 Category: Drugs & Pharmacology Source Type: research
Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects
ConclusionThis trial supports dosing oral semaglutide in accordance with prescribing information, which requires dosing in the fasting state.Trial RegistrationClinicalTrials.gov (NCT04513704); registered August 14, 2020. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - March 17, 2023 Category: Drugs & Pharmacology Source Type: research
Clearance as an Early Indicator of Efficacy for Therapeutic Monoclonal Antibodies: Circumventing Dose Selection Challenges in Oncology
ConclusionsClearance of mAbs can be a tumor/drug target-agnostic biomarker for potential anti-tumor activity as clearance decreases with increasing ORR. Our findings shed important insights into target clearance values that may lead to desired efficacy for different cancers and drug targets, which can be used to guide dose selection for the future development of mAbs during FIH oncology studies. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - March 17, 2023 Category: Drugs & Pharmacology Source Type: research
